P1591Cardiovascular toxicity of ibrutinib: a pharmacovigilance study
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz748.0350
Abstract: Ibrutinib, a first in class Bruton tyrosine kinase inhibitor, has revolutionized treatment for several B-cell malignancies. However, early data suggested that ibrutinib was associated with supra-ventricular arrhythmias (SVA) and bleeding. Other types of cardiovascular adverse… read more here.
Keywords: ibrutinib; ror ic025; pharmacovigilance study; days iqr ... See more keywords